News Ethics and Policy Drug Discovery

Regulatory Agencies Establish Principles of Good AI Use in Drug Development

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) developed a set of 10 guiding principles for good uses of artificial intelligence (AI) in drug development.

January 20, 2026 By ASCO AI Staff 2 min read
Share

0 Key Takeaways

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.

KOL Commentary
Watch

Related Content